These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 36167246)

  • 1. Real-world experience of esketamine use to manage treatment-resistant depression: A multicentric study on safety and effectiveness (REAL-ESK study).
    Martinotti G; Vita A; Fagiolini A; Maina G; Bertolino A; Dell'Osso B; Siracusano A; Clerici M; Bellomo A; Sani G; d'Andrea G; Chiaie RD; Conca A; Barlati S; Di Lorenzo G; De Fazio P; De Filippis S; Nicolò G; Rosso G; Valchera A; Nucifora D; Di Mauro S; Bassetti R; Martiadis V; Olivola M; Belletti S; Andriola I; Di Nicola M; Pettorruso M; McIntyre RS; di Giannantonio M;
    J Affect Disord; 2022 Dec; 319():646-654. PubMed ID: 36167246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treating bipolar depression with esketamine: Safety and effectiveness data from a naturalistic multicentric study on esketamine in bipolar versus unipolar treatment-resistant depression.
    Martinotti G; Dell'Osso B; Di Lorenzo G; Maina G; Bertolino A; Clerici M; Barlati S; Rosso G; Di Nicola M; Marcatili M; d'Andrea G; Cavallotto C; Chiappini S; De Filippis S; Nicolò G; De Fazio P; Andriola I; Zanardi R; Nucifora D; Di Mauro S; Bassetti R; Pettorruso M; McIntyre RS; Sensi SL; di Giannantonio M; Vita A;
    Bipolar Disord; 2023 May; 25(3):233-244. PubMed ID: 36636839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Esketamine in treatment-resistant depression patients comorbid with substance-use disorder: A viewpoint on its safety and effectiveness in a subsample of patients from the REAL-ESK study.
    Chiappini S; d'Andrea G; De Filippis S; Di Nicola M; Andriola I; Bassetti R; Barlati S; Pettorruso M; Sensi S; Clerici M; Dell'Osso B; Vita A; Martinotti G
    Eur Neuropsychopharmacol; 2023 Sep; 74():15-21. PubMed ID: 37148637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigating the Effectiveness and Tolerability of Intranasal Esketamine Among Older Adults With Treatment-Resistant Depression (TRD): A Post-hoc Analysis from the REAL-ESK Study Group.
    d'Andrea G; Chiappini S; McIntyre RS; Stefanelli G; Carullo R; Andriola I; Zanardi R; Martiadis V; Sensi SL; Sani G; Clerici M; Di Lorenzo G; Vita A; Pettorruso M; Martinotti G
    Am J Geriatr Psychiatry; 2023 Dec; 31(12):1032-1041. PubMed ID: 37479669
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting outcome with Intranasal Esketamine treatment: A machine-learning, three-month study in Treatment-Resistant Depression (ESK-LEARNING).
    Pettorruso M; Guidotti R; d'Andrea G; De Risio L; D'Andrea A; Chiappini S; Carullo R; Barlati S; Zanardi R; Rosso G; De Filippis S; Di Nicola M; Andriola I; Marcatili M; Nicolò G; Martiadis V; Bassetti R; Nucifora D; De Fazio P; Rosenblat JD; Clerici M; Maria Dell'Osso B; Vita A; Marzetti L; Sensi SL; Di Lorenzo G; McIntyre RS; Martinotti G;
    Psychiatry Res; 2023 Sep; 327():115378. PubMed ID: 37574600
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The rapid antidepressant effectiveness of repeated dose of intravenous ketamine and intranasal esketamine: A post-hoc analysis of pooled real-world data.
    d'Andrea G; Pettorruso M; Di Lorenzo G; Rhee TG; Chiappini S; Carullo R; Barlati S; Zanardi R; Rosso G; Di Nicola M; Andriola I; Marcatili M; Clerici M; Dell'Osso BM; Sensi SL; Mansur RB; Rosenblat JD; Martinotti G; McIntyre RS
    J Affect Disord; 2024 Mar; 348():314-322. PubMed ID: 38145840
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Esketamine nasal spray in patients with treatment-resistant depression: the real-world experience in the French cohort early-access programme.
    Samalin L; Rothärmel M; Mekaoui L; Gaudré-Wattinne E; Codet MA; Bouju S; Sauvaget A
    Int J Psychiatry Clin Pract; 2022 Nov; 26(4):352-362. PubMed ID: 35174754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of fixed doses of intranasal Esketamine as an add-on therapy to Oral antidepressants in Japanese patients with treatment-resistant depression: a phase 2b randomized clinical study.
    Takahashi N; Yamada A; Shiraishi A; Shimizu H; Goto R; Tominaga Y
    BMC Psychiatry; 2021 Oct; 21(1):526. PubMed ID: 34696742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Exploring vortioxetine combination with intranasal esketamine: A feasible alternative to SSRI/SNRI? - Insights from the REAL-ESK study.
    d'Andrea G; Miuli A; Pettorruso M; Cavallotto C; Marrangone C; Cocco A; De Filippis S; Martiadis V; Andriola I; Barlati S; Vita A; Dell'Osso BM; Sensi SL; Di Lorenzo G; Martinotti G
    J Affect Disord; 2024 Dec; 367():583-588. PubMed ID: 39233241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment patterns, healthcare utilization, and costs of patients with treatment-resistant depression initiated on esketamine intranasal spray and covered by US commercial health plans.
    Joshi K; Pilon D; Shah A; Holiday C; Karkare S; Zhdanava M
    J Med Econ; 2023; 26(1):422-429. PubMed ID: 36924214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and Safety of Esketamine Nasal Spray in Patients with Treatment-Resistant Depression Who Completed a Second Induction Period: Analysis of the Ongoing SUSTAIN-3 Study.
    Castro M; Wilkinson ST; Al Jurdi RK; Petrillo MP; Zaki N; Borentain S; Fu DJ; Turkoz I; Sun L; Brown B; Cabrera P
    CNS Drugs; 2023 Aug; 37(8):715-723. PubMed ID: 37558912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and Tolerability of Two Novel "Standard of Care" Treatments-Intranasal Esketamine Versus Intravenous Ketamine-for Treatment-Resistant Depression in Naturalistic Clinical Practice: Protocol for a Pilot Observational Study.
    Gutierrez G; Rosenblat J; Hawken E; Swainson J; Vazquez G
    JMIR Res Protoc; 2022 May; 11(5):e34711. PubMed ID: 35604752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of esketamine nasal spray on depressive symptom severity in adults with treatment-resistant depression and associations between the Montgomery-Åsberg Depression Rating Scale and the 9-item Patient Health Questionnaire.
    Kern Sliwa J; Naranjo RR; Turkoz I; Petrillo MP; Cabrera P; Trivedi M
    CNS Spectr; 2024 Jun; 29(3):176-186. PubMed ID: 38557430
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ; Trivedi MH; Janik A; Li H; Zhang Y; Li X; Lane R; Lim P; Duca AR; Hough D; Thase ME; Zajecka J; Winokur A; Divacka I; Fagiolini A; Cubala WJ; Bitter I; Blier P; Shelton RC; Molero P; Manji H; Drevets WC; Singh JB
    JAMA Psychiatry; 2019 Sep; 76(9):893-903. PubMed ID: 31166571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
    Popova V; Daly EJ; Trivedi M; Cooper K; Lane R; Lim P; Mazzucco C; Hough D; Thase ME; Shelton RC; Molero P; Vieta E; Bajbouj M; Manji H; Drevets WC; Singh JB
    Am J Psychiatry; 2019 Jun; 176(6):428-438. PubMed ID: 31109201
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exploring Esketamine's Therapeutic Outcomes as an FDA-Designated Breakthrough for Treatment-Resistant Depression and Major Depressive Disorder With Suicidal Intent: A Narrative Review.
    Kumari S; Chaudhry HA; Sagot A; Doumas S; Abdullah H; Alcera E; Solhkhah R; Afzal S
    Cureus; 2024 Feb; 16(2):e53987. PubMed ID: 38476783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Clinical Practice Among Patients With Treatment-Refractory Depression: An Observational Study.
    Singh B; Kung S; Pazdernik V; Schak KM; Geske J; Schulte PJ; Frye MA; Vande Voort JL
    J Clin Psychiatry; 2023 Feb; 84(2):. PubMed ID: 36724113
    [No Abstract]   [Full Text] [Related]  

  • 18. Efficacy and safety of adjunctive therapy using esketamine or racemic ketamine for adult treatment-resistant depression: A randomized, double-blind, non-inferiority study.
    Correia-Melo FS; Leal GC; Vieira F; Jesus-Nunes AP; Mello RP; Magnavita G; Caliman-Fontes AT; Echegaray MVF; Bandeira ID; Silva SS; Cavalcanti DE; Araújo-de-Freitas L; Sarin LM; Tuena MA; Nakahira C; Sampaio AS; Del-Porto JA; Turecki G; Loo C; Lacerda ALT; Quarantini LC
    J Affect Disord; 2020 Mar; 264():527-534. PubMed ID: 31786030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of esketamine nasal spray by sex in patients with treatment-resistant depression: findings from short-term randomized, controlled trials.
    Jones RR; Freeman MP; Kornstein SG; Cooper K; Daly EJ; Canuso CM; Nicholson S
    Arch Womens Ment Health; 2022 Apr; 25(2):313-326. PubMed ID: 34973081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Practical recommendations for the management of treatment-resistant depression with esketamine nasal spray therapy: Basic science, evidence-based knowledge and expert guidance.
    Kasper S; Cubała WJ; Fagiolini A; Ramos-Quiroga JA; Souery D; Young AH
    World J Biol Psychiatry; 2021 Jul; 22(6):468-482. PubMed ID: 33138665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.